JP2010518153A - ピロロ［２，３−ｂ］ピリジン化合物、該ピロロ［２，３−ｂ］ピリジン化合物を合成するために用いられるアザインドール化合物、それらの製造方法、及びそれらの使用 - Google Patents

ピロロ［２，３−ｂ］ピリジン化合物、該ピロロ［２，３−ｂ］ピリジン化合物を合成するために用いられるアザインドール化合物、それらの製造方法、及びそれらの使用 Download PDF

Info

Publication number
JP2010518153A
JP2010518153A JP2009549445A JP2009549445A JP2010518153A JP 2010518153 A JP2010518153 A JP 2010518153A JP 2009549445 A JP2009549445 A JP 2009549445A JP 2009549445 A JP2009549445 A JP 2009549445A JP 2010518153 A JP2010518153 A JP 2010518153A
Authority
JP
Japan
Prior art keywords
group
pyrrolo
pyridine
pyrimidin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518153A5 (enExample
Inventor
ローラン マイヤー
ベノワ ジョゼフ
フランソワ リゲル
ベルナール マルケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Claude Bernard Lyon 1
Original Assignee
Université Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Claude Bernard Lyon 1 filed Critical Université Claude Bernard Lyon 1
Publication of JP2010518153A publication Critical patent/JP2010518153A/ja
Publication of JP2010518153A5 publication Critical patent/JP2010518153A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009549445A 2007-02-16 2008-02-14 ピロロ［２，３−ｂ］ピリジン化合物、該ピロロ［２，３−ｂ］ピリジン化合物を合成するために用いられるアザインドール化合物、それらの製造方法、及びそれらの使用 Pending JP2010518153A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0701138A FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
PCT/FR2008/000197 WO2008129152A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Publications (2)

Publication Number Publication Date
JP2010518153A true JP2010518153A (ja) 2010-05-27
JP2010518153A5 JP2010518153A5 (enExample) 2011-03-31

Family

ID=38515529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549445A Pending JP2010518153A (ja) 2007-02-16 2008-02-14 ピロロ［２，３−ｂ］ピリジン化合物、該ピロロ［２，３−ｂ］ピリジン化合物を合成するために用いられるアザインドール化合物、それらの製造方法、及びそれらの使用

Country Status (6)

Country Link
US (1) US20100184790A1 (enExample)
EP (1) EP2125803B1 (enExample)
JP (1) JP2010518153A (enExample)
CA (1) CA2678007A1 (enExample)
FR (1) FR2912744B1 (enExample)
WO (1) WO2008129152A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505584A (ja) * 2012-12-18 2016-02-25 サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） ダウン症候群及びアルツハイマー病に関連する認知欠損の治療のための、ｄｙｒｋ１ａタンパク質阻害剤としての３，５−ジアリールアザインドール類
JP2016540794A (ja) * 2013-12-17 2016-12-28 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
JP2020520381A (ja) * 2017-03-23 2020-07-09 テグ−キョンプク メディカル イノベーション ファウンデーション ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728559A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US8435980B2 (en) * 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
EP3383875B1 (en) 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
CN111278840B (zh) * 2017-08-18 2023-11-17 癌症研究科技有限公司 吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
CN110759892B (zh) * 2018-07-26 2022-09-13 南开大学 Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN109096257B (zh) * 2018-08-09 2020-02-21 山东博苑医药化学有限公司 Meridianin类生物碱及其衍生物在防治植物病毒病菌病中的应用
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
CN109879874A (zh) * 2019-03-05 2019-06-14 常州大学 一种Meriolin的合成方法
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
EP1957488B1 (en) * 2005-11-30 2009-09-09 F.Hoffmann-La Roche Ag 3-amino-2-arylpropyl azaindoles and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505584A (ja) * 2012-12-18 2016-02-25 サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） ダウン症候群及びアルツハイマー病に関連する認知欠損の治療のための、ｄｙｒｋ１ａタンパク質阻害剤としての３，５−ジアリールアザインドール類
JP2016540794A (ja) * 2013-12-17 2016-12-28 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
JP2020520381A (ja) * 2017-03-23 2020-07-09 テグ−キョンプク メディカル イノベーション ファウンデーション ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物

Also Published As

Publication number Publication date
US20100184790A1 (en) 2010-07-22
EP2125803B1 (fr) 2013-04-10
CA2678007A1 (fr) 2008-10-30
WO2008129152A1 (fr) 2008-10-30
FR2912744B1 (fr) 2012-09-07
FR2912744A1 (fr) 2008-08-22
EP2125803A1 (fr) 2009-12-02

Similar Documents

Publication Publication Date Title
US20100184790A1 (en) Pyrrolo[2,3-b]pyridine compounds, azaindole compounds used for synthesizing said pyrrolo[2,3-b]pyridine compounds, methods for the production thereof, and uses thereof
JP7074903B2 (ja) イミダゾピリダジン化合物
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6713982B2 (ja) ピラゾロピリミジン化合物
US20200121686A1 (en) N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
EP3858833B1 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
CN103619841A (zh) 杂芳基化合物及其使用方法
CN111051304B (zh) 作为LRRK2抑制剂的咪唑并[4,5-c]喹啉衍生物
US6869956B2 (en) Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
KR20150037950A (ko) 4-메틸-2,3,5,9,9ｂ-펜타아자-사이클로펜타[ａ]나프탈렌
CN105121439A (zh) 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
JP6786566B2 (ja) ヘテロアリール化合物及びその使用方法
US10934300B2 (en) Atropisomerism for enhanced kinase inhibitor selectivity
US20210188863A1 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP6837072B2 (ja) ６，７−ジヒドロ−５Ｈ−ピラゾロ［５，１−ｂ］［１，３］オキサジン−２−カルボキサミド化合物
CN109641902B (zh) 可用作人pde1抑制剂的三唑并吡嗪酮衍生物
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
KR20150036126A (ko) 포스포디에스테라아제 10 효소의 억제제
TWI670271B (zh) [1,2,4]三唑并[4,3-a]吡-6(5h)-酮衍生物
TWI659955B (zh) 取代的三環雜環化合物及其用途
JP2017075116A (ja) 新規縮合複素環化合物
HK1260037B (en) Substituted tricyclic herteocyclic compounds and use thereof
TW201600520A (zh) 雜環化合物
HK1129105B (en) Pyrazolo[1,5-a] pyrimidines, processes, uses and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105